Silence Therapeutics (SLN) Cash from Financing Activities (2020 - 2025)
Silence Therapeutics recorded quarterly Cash from Financing Activities of $1000.0 in Q2 2025, down 92.86% quarter-over-quarter from $14000.0 in Q1 2025, and down 99.91% year-over-year from $1.1 million in Q2 2024.
Silence Therapeutics' Cash from Financing Activities history runs 6 years deep, the most recent figure standing at $1000.0 for Q2 2025.
- In Q2 2025, Cash from Financing Activities fell 99.91% year-over-year to $1000.0; the TTM figure through Mar 2026 stood at $1000.0 (down 99.99% YoY), while the FY2025 annual figure was $15000.0, down 99.99% from the prior year.
- Cash from Financing Activities came in at $1000.0 for Q2 2025 at Silence Therapeutics, down from $14000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $133.0 million in Q1 2024 to a low of -$98000.0 in Q4 2024.
- A 5-year average of $15.7 million and a median of $585897.9 in 2021 frame the typical range for Cash from Financing Activities.
- On a YoY basis, Cash from Financing Activities climbed as much as 575876.78% in 2024 and fell as far as 100.8% in 2024.
- Silence Therapeutics' Cash from Financing Activities stood at $585897.9 in 2021, then slumped by 91.19% to $51608.8 in 2022, then soared by 23756.81% to $12.3 million in 2023, then sank by 100.8% to -$98000.0 in 2024, then surged by 101.02% to $1000.0 in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $1000.0, $14000.0, and -$98000.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Silence Therapeutics | 924.61 Mn | 854.53 Mn | 411,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Mar 31, 2025 | 14,000.00 |
| Mar 31, 2025 | 14,000.00 |
| Dec 31, 2024 | -98,000.00 |
| Dec 31, 2024 | -98,000.00 |
| Sep 30, 2024 | 7.75 Mn |
| Sep 30, 2024 | 7.75 Mn |
| Jun 30, 2024 | 1.07 Mn |
| Jun 30, 2024 | 1.07 Mn |
| Mar 31, 2024 | 133.02 Mn |
| Mar 31, 2024 | 133.02 Mn |
| Dec 31, 2023 | 12.31 Mn |
| Dec 31, 2023 | 12.31 Mn |
| Sep 30, 2023 | 15.24 Mn |
| Sep 30, 2023 | 15.24 Mn |
| Jun 30, 2023 | 3.98 Mn |
| Jun 30, 2023 | 3.98 Mn |
| Mar 31, 2023 | 23,094.68 |
| Mar 31, 2023 | 23,094.68 |
| Dec 31, 2022 | 51,608.85 |
| Dec 31, 2022 | 51,608.85 |
| Sep 30, 2022 | 50.75 Mn |
| Sep 30, 2022 | 50.75 Mn |
| Jun 30, 2022 | -13,852.46 |
| Jun 30, 2022 | -13,852.46 |
| Mar 31, 2022 | -63,066.28 |
| Mar 31, 2022 | -63,066.28 |
| Sep 30, 2021 | 585,897.92 |
| Sep 30, 2021 | 585,897.92 |
| Jun 30, 2021 | -86,659.15 |
| Jun 30, 2021 | -86,659.15 |
| Mar 31, 2021 | 41.85 Mn |
| Mar 31, 2021 | 41.85 Mn |
| Dec 31, 2020 | -139,967.81 |
| Dec 31, 2020 | -139,967.81 |